The ACT NOW:END AIDS Coalition, of which TAG is a founding member, released this statement today calling for the administration’s efforts to end the HIV epidemic to be rooted in fact, science, and sensible policies that are consistent with the stated goal of ending HIV.
Follow up to our 12/19 statement applauding Indian activists for taking legal action to oppose two patent applications filed by Sanofi in India. This joint statement from Treatment Action Group and OTMeds urges Sanofi to deliver on its promise to withdraw in all countries where the applications were filed and are still pending.
Treatment Action Group (TAG) applauds the legal actions undertaken by our colleagues from the Delhi Network of Positive People (DNP+) and tuberculosis (TB) survivor and activist Ganesh Acharya of Mumbai, with support from the Third World Network (TWN), contesting two patent applications on combinations of two decades-old TB medicines filed in India by French pharmaceutical company Sanofi.
The high cost of GeneXpert tests for tuberculosis (TB) leaves open a critical gap in the diagnosis of TB and fails to consider volume of sales and public investments in the development of GeneXpert.
October 31, 2019 — Civil society and community-based organizations issued this letter welcoming the availability of lower-priced rifapentine, which is an essential medicine for preventing TB. However, while all the organizations agree that this discount is a step forward, they're…
The purpose of this new publication is to provide information for you and your community. The Activist Guide aims to provide a deeper focus on diagnosis with updated information about the steps and different technologies involved in diagnosing a person with hepatitis C.
Presented at the 50th Union World Conference on Lung Health, an analysis by Treatment Action Group (TAG) finds that total public expenditures on the development of bedaquiline –– an important medicine for drug-resistant tuberculosis (DR-TB) –– far exceed those of the originator company, Johnson & Johnson.
Letter from Organizations and Individuals to Cepheid asking them to reduce the price of Xpert MTB/RIF and Xpert MTB/RIF Ultra cartridges to US $5, inclusive of service and maintenance.
By Bryn Gay, HCV Project Director, TAG Access to medicines (A2M) activists have become better coordinated, articulate, and adept in responding to pharmaceutical industry shenanigans that threaten access to affordable medicines since the establishment of harmonized global intellectual property (IP) …
Activists from around the world called on National TB Programs to discontinue routine use of harmful injectable agents in treatment regimens for drug-resistant tuberculosis, in favor of newer, safer World Health Organization (WHO)-recommended treatments.